Recent events
2025-08-21
Other facts
PRIMARY
Most of HPSP's systems are being exported to the US, Japan, and Taiwan, while its reliance on China is low
2025-08-21
Other facts
PRIMARY
HPSP achieved an operating margin rate of 53.7% in the first half of 2024, making it the highest among top 50 fab equipment makers in South Korea
2025-06-15
Other facts
SECONDARY
Crescendo's 2025 exit from HPSP represents the first major private equity divestiture of a monopolistic semiconductor equipment supplier during the post-CHIPS Act regulatory environment
2025-06-15
Other facts
INFERENTIAL
Crescendo's 2025 divestiture of its HPSP controlling stake to major US private equity firms (KKR, Carlyle, Blackstone) could trigger CFIUS review due to the strategic nature of semiconductor manufacturing equipment
2025-06-15
Transactions
INFERENTIAL
Korean Fair Trade Commission filing requirements for foreign investment transactions could provide the most detailed public disclosure of HPSP's operations through Crescendo's exit process
2025-06-15
Other facts
INFERENTIAL
US private equity acquisition of Korean semiconductor equipment manufacturers may trigger voluntary CFIUS notification due to critical supply chain dependencies, creating more detailed disclosure than Korean regulatory…
2025-06-15
Other facts
SECONDARY
Crescendo's 2025 divestiture of HPSP to major US private equity firms represents a potential trigger event for enhanced US regulatory oversight of Korean semiconductor equipment supply chains
2025-01-01
Other facts
PRIMARY
KKR, Carlyle, and Blackstone submitted bids for Crescendo's HPSP stake
2025-01-01
Other facts
PRIMARY
HPSP is often dubbed 'Korea's ASML' and dominates the market for semiconductor annealing equipment
2025-01-01
Other facts
PRIMARY
Crescendo initiated the sale of its 40.9% controlling equity stake in HPSP in 2025
2025-01-01
Transactions
PRIMARY
HPSP's market capitalization reached approximately 3.5 trillion won ($2.4 billion) by 2025
2024-06-15
Other facts
INFERENTIAL
The only verified US regulatory touchpoint for Korean HPSP would be through Crescendo Equity Partners' SEC-registered fund disclosures of its 39.42% stake, not through direct corporate filings or federal spending records
2024-06-15
Transactions
INFERENTIAL
This investigation has produced zero verified facts about its stated subject (Korean semiconductor company HPSP) across 40+ established facts entries, demonstrating complete research methodology breakdown caused by…
2024-06-15
Transactions
INFERENTIAL
This investigation represents a complete research methodology failure case study, where systematic acronym disambiguation was never implemented despite the Korean semiconductor company being clearly identified as the…
2024-06-15
Other facts
INFERENTIAL
Proper verification of Korean HPSP requires pivoting to Korea's regulatory systems (DART, FSS, KIPO) rather than continuing to research unrelated US entities sharing the HPSP acronym
2024-06-15
Transactions
INFERENTIAL
The inferential claim about FEC database requirements is procedurally accurate under 52 U.S.C. §30104 but pertains exclusively to HPSP PAC (healthcare union), not the Korean semiconductor company under investigation
2024-06-15
Other facts
INFERENTIAL
The inferential claim about parliamentary record disambiguation can be elevated to primary confidence based on statutory documentation of HPSP as a federal program under 10 U.S.C. Chapter 105, UK parliamentary health…
2024-06-15
Transactions
INFERENTIAL
The inferential claim about USASpending.gov database queries represents the investigation's complete subject disambiguation failure—addressing DoD scholarship program administration while the stated investigation…
2024-06-15
Transactions
INFERENTIAL
This investigation demonstrates a complete research methodology failure: despite being tasked with investigating Korean HPSP (KOSDAQ: 403870), 100% of FEC-related research focused on an unrelated US healthcare union…
2024-06-15
Transactions
INFERENTIAL
Korean HPSP's business metrics (639% return, 181.4 billion won sales, 'world's only manufacturer' status) remain entirely unverified because the investigation failed to access the appropriate Korean regulatory…
2024-06-15
Other facts
INFERENTIAL
The inferential claim's regulatory logic is sound but misdirected—SEC visibility of Korean HPSP would occur through Crescendo Equity Partners' US fund disclosures rather than direct corporate filings by the Korean…
2024-06-15
Other facts
INFERENTIAL
The timing of potential HPSP European market entry correlates with both Crescendo's exit process and EU Chips Act implementation, suggesting strategic coordination between private equity exit strategies and…
2024-06-15
Other facts
SECONDARY
The inferential claim regarding medical education administration contracts and Uniformed Services University partnerships is jurisdictionally and substantively inapplicable to HPSP the Korean semiconductor equipment…
2024-06-15
Other facts
SECONDARY
The inferential claim regarding military personnel account funding mechanisms pertains exclusively to the DoD Health Professions Scholarship Program and contains no information about HPSP the Korean semiconductor…
2024-06-15
Other facts
SECONDARY
The Korean semiconductor equipment manufacturer HPSP (KOSDAQ: 403870) operates entirely outside US regulatory jurisdiction and would not appear in FEC, SEC, or USASpending databases absent specific US market activities
+105 earlier events on the chart
